J&J: positive data for lung cancer drug
(CercleFinance.com) - Johnson & Johnson's Janssen Pharmaceutical Companies yesterday announced long-term results from a study of the combination of Rybrevant (amivantamab-vmjw) and lazertinib as first-line treatment for patients with EGFR-mutated non-small cell lung cancer (NSCLC).
These results and additional data were presented at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting. The estimated progression-free survival rate was 85% at one year, 65% at two years and 51% at three years. The longest duration of ongoing treatment was more than three years (37.2 months) and the longest median duration of response was nearly three years (35.7 months). Copyright (c) 2023 CercleFinance.com. All rights reserved. |
22/09/2023 17:20
Uberen hausse, un analyste relève son objectif 22/09/2023 17:11 BMWnomination à la direction de Sylvia Neubauer 22/09/2023 17:07 Deerele titre chute, plombé par une dégradation d'analyste 22/09/2023 16:56 Amazonde la publicité sur Prime Video à partir de 2024 22/09/2023 16:30 BMWnouveau responsable de BMW Motorrad Design 22/09/2023 16:11 Diageodeux nominations à la direction aux Etats Unis Tous les articles sociétés |
